BMC endocrine disorders · 2026
Prevalence of poor glycemic control in diabetic hypertensive patients: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bosho Dula Dessalegn, Guracho Yonas Deressa, Asmare Selamawit Worku, Tesfaye Behailu Terefe, Olana Diriba Dereje, Birhanu Tesema Etefa
Аннотация
INTRODUCTION: Poor glycemic control is a significant public health issue, contributing to the development of complications, increasing healthcare costs, and quality of life. The objective of the meta-analysis is to estimate the prevalence of poor glycemic control and its prevalence according to diagnostic criteria in diabetic hypertensive patients. Findings will be critical in reducing the burden of poor glycemic control and complications.
METHODS: A systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. Three electronic databases (PubMed, Web of Science, and SCOPUS) were searched for studies published in English between January 2015 and January 2025. Primary studies assessed glycemic control among diabetic-hypertensive patients using one or more of the following: a fasting blood glucose (FBG) level (> 126 mg/dL, > 130 mg/dL, or > 130 mg/dL) and/or glycated hemoglobin A1C level (≥ 7%). Random-effects models (metaprop, REML) were used to estimate pooled prevalence. Heterogeneity, sensitivity test, subgroup analysis, and publication bias assessments were performed.
RESULTS: In this study, ten papers involving a total of 2552 individuals were utilized to derive the pooled estimate. The pooled prevalence of poor glycemic control was 59% (95%CI; 0.49-0.69). Based on diagnostic criteria the pooled prevalence of poor glycemic control in diabetic hypertensive patients was 46% (95%CI: 0.31-0.61), and 65% (95%CI; 0.54-0.76) for fasting blood glucose and glycosylated hemoglobin respectively. There is substantial heterogeneity but no significant publication bias on visual inspection of the forest plot.
CONCLUSION: Around two-third of study participants have poor glycemic control in diabetic hypertensive patients. This finding is important as a baseline for refining clinical guidelines and improving long-term outcomes for this high-risk group. Future researchers will evaluate effective interventions to improve glycemic control in diabetic hypertensive patients across diverse study settings.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: A systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. Three electronic databases (PubMed, Web of Science, and SCOPUS) were searched for studies published in English between January 2015 and January 2025. Primary studies assessed glycemic control among diabetic-hypertensive patients using one or more of the following: a fasting blood glucose (FBG) level (> 126 mg/dL, > 130 mg/dL, or > 130 mg/dL) and/or glycated hemoglobin A1C level (≥ 7%). Random-effects models (metaprop, REML) were used to estimate pooled prevalence. Heterogeneity, sensitivity test, subgroup analysis, and publication bias assessments were performed.
RESULTS: In this study, ten papers involving a total of 2552 individuals were utilized to derive the pooled estimate. The pooled prevalence of poor glycemic control was 59% (95%CI; 0.49-0.69). Based on diagnostic criteria the pooled prevalence of poor glycemic control in diabetic hypertensive patients was 46% (95%CI: 0.31-0.61), and 65% (95%CI; 0.54-0.76) for fasting blood glucose and glycosylated hemoglobin respectively. There is substantial heterogeneity but no significant publication bias on visual inspection of the forest plot.
CONCLUSION: Around two-third of study participants have poor glycemic control in diabetic hypertensive patients. This finding is important as a baseline for refining clinical guidelines and improving long-term outcomes for this high-risk group. Future researchers will evaluate effective interventions to improve glycemic control in diabetic hypertensive patients across diverse study settings.
CLINICAL TRIAL NUMBER: Not applicable.